February 29, 2016 / 2:01 PM / 4 years ago

AstraZeneca cancer drug fails in mesothelioma trial

LONDON, Feb 29 (Reuters) - AstraZeneca said a closely watched experimental cancer drug failed in a clinical trial when used on its own to treat mesothelioma, a rare lung and abdominal cancer, but it remained confident the drug had a role to play in combination treatments.

Tremelimumab failed to meet the primary endpoint of improving overall survival in hard-to-treat mesothelioma patients, the drugmaker said on Monday.

Tremelimumab is also being tested in combination with another of AstraZeneca’s immune-boosting drugs called durvalumab in multiple tumour types, including non-small cell lung cancer.

Reporting by Ben Hirschler; Editing by Kate Kelland

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below